Development of prophylactic and therapeutic vaccines against hepatitis C virus (Q36198667)

12 August 2017

1 reference

title

Development of prophylactic and therapeutic vaccines against hepatitis C virus (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

1

Geert Leroux-Roels

0 references

language of work or name

1 reference

1 June 2005

1 reference

Expert Review of Vaccines

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

351-371

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Prevention of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C: molecular virology and antiviral targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Characterization of pseudotype VSV possessing HCV envelope proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Determination of antigen-specific memory/effector CD4 T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

In situ detection of virus- and tumor-specific T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus and interferon resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Presence of functional dendritic cells in patients chronically infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

The lineage decisions of helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Association of hepatitis C virus-specific CD8 T cells with viral clearance in acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Broad Specificity of Virus-Specific CD4 T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Frequencies of HCV-specific effector CD4 T cells by flow cytometry: correlation with clinical disease stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Recurrence of hepatitis C virus after loss of virus-specific CD4( ) T-cell response in acute hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Determinants of viral clearance and persistence during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Analysis of successful immune responses in persons infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Memory CD8 T cells are required for protection from persistent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Impaired effector function of hepatitis C virus-specific CD8 T cells in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Antigen-induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

CD4 CD25 regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Limited humoral immunity in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Neutralizing antibody response during acute and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immunity in hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Vaccination of chimpanzees against infection by the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Protection against persistence of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Cross-genotype immunity to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Vaccine development for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

The challenge of developing a vaccine against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-alpha promoter elicits HCV-specific cytotoxic T-lymphocytes (CTL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

DNA vaccination for the induction of immune responses against hepatitis C virus proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

A truncated variant of the hepatitis C virus core induces a slow but potent immune response in mice following DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immunization with a DNA vaccine encoding the hepatitis-C-virus structural antigens elicits a specific immune response against the capsid and envelope proteins in rabbits and Macaca irus (crab-eating macaque monkeys).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4 T-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Efficient induction of T helper 1 CD4 T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

A liposomal peptide vaccine inducing CD8 T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

DNA vaccines for hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Inhibition of Tumor Necrosis Factor (TNF-α)-mediated Apoptosis by Hepatitis C Virus Core Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus core and envelope proteins do not suppress the host's ability to clear a hepatic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Future trends in managing hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Therapeutic vaccination against chronic viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Optimal Induction of T-Cell Responses against Hepatitis C Virus E2 by Antigen Engineering in DNA Immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Structural biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

Hepatic expansion of a virus-specific regulatory CD8 T cell population in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14760584.4.3.351

21 January 2018

Identifiers

DOI

10.1586/14760584.4.3.351

1 reference

12 August 2017

1 reference